A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07232589
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Nemtabrutinib — DRUG
    Oral administration
  • Diltiazem — DRUG
    Oral administration

Study Details

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.

Key Dates

Start date
Dec 8, 2025
Status verified
May 2026
Primary completion
May 4, 2026
Completion
May 16, 2026

Study Design

Enrollment
26 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Period 1: Nemtabrutinib
    Participants will receive nemtabrutinib followed by a protocol specified wash-out period.
  • Experimental: Period 2: Diltiazem + Nemtabrutinib
    Participants will receive diltiazem plus nemtabrutinib.

Primary Outcome Measure

Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Nemtabrutinib [ Time Frame: Up to approximately 4 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortea CRU Madison ( Site 0001)MadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortea CRU Madison· Madison, WI

Related Studies